Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Micro Cap & Branchenriese: Heute rein? - Partnerschaft entfacht Übernahmefantasien!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
604 Leser
Artikel bewerten:
(2)

Deriv Group: Deriv's new partnership with Puttinu Cares: United for children's cancer support in Malta

Finanznachrichten News

Taking a pivotal step in community support for Maltese children battling cancer

Carnival party preparations by the Deriv team.

Carnival party preparations by the Deriv team

QAWRA, Malta, March 28, 2024 (GLOBE NEWSWIRE) -- In a significant step to support Maltese children with cancer, Deriv, a global online trading broker, has partnered with Puttinu Cares, a renowned Maltese non-governmental organisation dedicated to helping children with cancer and their families. This collaboration is a major part of Deriv's corporate social responsibility programme, highlighting the company's commitment to hosting a series of engaging and supportive events over six months starting January 2024.

Therese Cardona, Office Manager at Deriv Malta, expressed, "Our partnership with Puttinu Cares embodies our dedication to engaging with and supporting the communities in which we operate. We strive to contribute significantly to the children and their families by utilising our resources and expertise. As part of our CSR strategy, we are leveraging Deriv's skills to mobilise support and raise awareness through this initiative. It aims to meet and support essential needs through active involvement and the allocation of resources."

Engagement and support: Deriv's hands-on involvement

  • Volunteer efforts at Puttinu Cares charity shops: Throughout January 2024, Deriv's Malta team dedicated their efforts to enhancing the operations of Puttinu Cares' charity shops in Qawra, Malta. Their activities ranged from sorting donations and managing the storefront to pricing items for sale, demonstrating a hands-on approach to supporting the charity's mission.
  • Carnival celebration highlights: On February 12, a carnival party organised by Deriv volunteers created a memorable day for the affected families. The party was designed to uplift the spirits of the children and their families. This initiative was a part of Deriv's broader commitment to creating positive, memorable moments for cancer patients and their families.

Forthcoming initiatives and continued commitment

Derivand Puttinu Cares are excited to announce more upcoming events designed to support further and uplift the children and families affected by cancer. This ongoing partnership reflects both organisations' dedication to making a tangible difference in the lives of those they serve.

Deriv volunteers at Puttinu Cares charity shop in Malta

Deriv volunteers at Puttinu Cares charity shop in Qawra, Malta

Echoing the sentiment, Kirsty Abela, a dedicated Deriv volunteer, shared, "Our experience has been incredibly heartwarming. It's more than volunteering; it's about making a difference where it truly counts. This initiative has brought us closer as a team and to the community we serve, showing the value of compassion and collective action."

This partnership is a part of 'Deriv Life', Deriv's extensive CSR programme, which includes global environmental conservation and community support initiatives. Over the past year, Deriv's CSR programme - 'Deriv Life', has been responsible for several significant initiatives, including environmental CSRin Cyprus, sponsoring a prosthetic limb for Malaysia's youngest elephant amputee, and sponsoring a team in the 4L Trophy rally. These actions reinforce Deriv's dedication to CSR as a core aspect of its identity and mission.

To learn more, visit Deriv Lifeand the company website.

About Deriv

For 25 years, Deriv has been committed to making online trading accessible to anyone, anywhere. Trusted by over 2.5 million traders worldwide, the company offers an expansive range of trade types and boasts over 200 assets across popular markets on its award-winning, intuitive trading platforms. With a workforce of more than 1,300 people globally, Deriv has cultivated an environment that celebrates achievements, encourages professional growth, and fosters talent development, which reflects in its Platinum accreditation by Investors in People.


PRESS CONTACT
pr@deriv.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/50f0d15b-a337-427a-90e0-e3fccfba7bc1
https://www.globenewswire.com/NewsRoom/AttachmentNg/957012cc-d102-4308-b6b1-5c2e54bc4e50


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.